Session » Abstracts: Patient Outcomes, Preferences, & Attitudes II: Patient Experience

Date: Tuesday, November 14, 2023

Time: 4:00PM-5:30PM

Meeting: ACR Convergence 2023

4:00PM-5:30PM: Abstract Number: 2534

A Novel Approach for Mixed-methods Research Using Language Learning Models: A Report Using Patients’ Perspectives on Barriers to Hip and Knee Replacement

4:00PM-5:30PM: Abstract Number: 2536

DMARD Adherence During the COVID-19 Pandemic and Association with Risk of COVID-19 Infection

4:00PM-5:30PM: Abstract Number: 2537

Implementation of a Best Practice Advisory to Improve Infection Screening Prior to New Prescriptions of Biologics and Targeted Synthetic Drugs

4:00PM-5:30PM: Abstract Number: 2533

Real-world Evidence for Assessing Mortality Disparity Between the Patients with Rheumatoid Arthritis and the General Population in Japan: Results from the IORRA Study

4:00PM-5:30PM: Abstract Number: 2538

Safety and Efficacy of Sodium-glucose Co-transporter 2 Inhibitors in Patients with Psoriasis and Concomitant Type 2 Diabetes Mellitus: A Population-based Cohort Study

4:00PM-5:30PM: Abstract Number: 2535

Strategies to Embrace Living with Lupus Fearlessly (SELF): A Promising Digital Intervention for Lupus Self-Management

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].